Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 1:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: SLE Nephritis Clear all
Recruiting No phase listed Observational

Research Accelerated by You Lupus Registry

NCT06927219
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Cutaneous Lupus Erythematosus (CLE)
Interventions
Not listed
Lead sponsor
Lupus Foundation of America
Other
Eligibility
Not listed
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2050
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jun 25, 2026, 1:59 PM EDT
Recruiting Phase 1Phase 2 Interventional

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

NCT06839976
View directory record Official record
Conditions
SLE, Systemic Lupus Erythematosus (SLE), CAR T Cell, CART19, Cell Therapy, Lupus, Lupus Nephritis (LN)
Interventions
CART19
Biological
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
12 Years to 29 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jun 25, 2026, 1:59 PM EDT
Recruiting Phase 1Phase 2 Interventional

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

NCT06121297
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Lupus Nephritis
Interventions
CABA-201
Biological
Lead sponsor
Cabaletta Bio
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
21
States / cities
Orange, California • Sacramento, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jun 25, 2026, 1:59 PM EDT
Completed Phase 2 Interventional

BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis

NCT00001789
View directory record Official record
Conditions
Glomerulonephritis, Membranoproliferative, Lupus Nephritis
Interventions
BG9588
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 25, 2026, 1:59 PM EDT
Completed No phase listed Observational

Dynamic Imaging of Variation in Lupus Nephritis

NCT03180021
View directory record Official record
Conditions
Lupus Nephritis
Interventions
MRI
Procedure
Lead sponsor
RILITE Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Aurora, Colorado • New York, New York • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2021 · Synced Jun 25, 2026, 1:59 PM EDT
Terminated Phase 3 Interventional

Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis

NCT05288855
View directory record Official record
Conditions
Adolescent Lupus Nephritis, Pediatric Lupus Nephritis
Interventions
Voclosporin, Placebo Oral Capsule
Drug
Lead sponsor
Aurinia Pharmaceuticals Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jun 25, 2026, 1:59 PM EDT
Completed Phase 3 Interventional Results available

A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.

NCT00377637
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Mycophenolate mofetil (MMF), Cyclophosphamide, Azathioprine, Placebo to Azathioprine, Placebo to Mycophenolate mofetil, Corticosteroid
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 75 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
28
States / cities
Huntsville, Alabama • La Jolla, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2011 · Synced Jun 25, 2026, 1:59 PM EDT
Terminated No phase listed Observational

Evaluation of Patients With Lupus Nephritis Using Kidney MRI (Magnetic Resonance Imaging)

NCT06445127
View directory record Official record
Conditions
SLE (Systemic Lupus)
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Jun 25, 2026, 1:59 PM EDT
Withdrawn Phase 1 Interventional

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus

NCT06429800
View directory record Official record
Conditions
Lupus Nephritis, Systemic Lupus Erythematosus
Interventions
ATA3219
Drug
Lead sponsor
Atara Biotherapeutics
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Thousand Oaks, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Jun 25, 2026, 1:59 PM EDT
Recruiting No phase listed Observational

Lupus Landmark Study: A Prospective Registry and Biorepository

NCT05934149
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Neuropsychiatric Systemic Lupus Erythematosus
Interventions
Not listed
Lead sponsor
Lupus Research Alliance
Other
Eligibility
18 Years to 110 Years
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
19
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jun 25, 2026, 1:59 PM EDT
Recruiting Phase 2 Interventional

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

NCT05538208
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Mycophenolate Mofetil
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 20 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
19
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jun 25, 2026, 1:59 PM EDT
Terminated Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)

NCT02176486
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Ixazomib, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
12
States / cities
La Jolla, California • Upland, California • Port Charlotte, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2019 · Synced Jun 25, 2026, 1:59 PM EDT
Terminated Phase 2 Interventional Results available

An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

NCT03943147
View directory record Official record
Conditions
Lupus Nephritis
Interventions
BMS-986165, Placebo, Mycophenolate Mofetil
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
40
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2022 · Synced Jun 25, 2026, 1:59 PM EDT
Terminated Phase 2 Interventional Results available

Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

NCT05540665
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Daxdilimab, Placebo (Normal Saline)
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Birmingham, Alabama • San Dimas, California • Syracuse, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Jun 25, 2026, 1:59 PM EDT
Terminated Phase 2 Interventional Results available

Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

NCT05097989
View directory record Official record
Conditions
Lupus Nephritis, Immunoglobulin A Nephropathy, IgAN, LN
Interventions
ALXN2050, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Huntsville, Alabama • Loma Linda, California • Northridge, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jun 25, 2026, 1:59 PM EDT
Completed Phase 3 Interventional Results available

Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin

NCT03597464
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Voclosporin, Placebo Oral Capsule
Drug
Lead sponsor
Aurinia Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Jun 25, 2026, 1:59 PM EDT
Recruiting Phase 4 Interventional

PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

NCT07611214
View directory record Official record
Conditions
Lupus Nephritis
Interventions
LUPKYNIS, belimumab, obinutuzumab or anifrolumab, mycophenolic acid analog (MPAA), corticosteroid
Drug · Biological
Lead sponsor
Aurinia Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
15
States / cities
La Mesa, California • Los Alamitos, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jun 25, 2026, 1:59 PM EDT
Recruiting Early Phase 1 Interventional

Safety and Efficacy of ONT01 in Lupus

NCT07107659
View directory record Official record
Conditions
Lupus Nephritis (LN), Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus, SLE, Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (Disorder)
Interventions
ONT01 is a small molecule CD11b modulator.
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Jun 25, 2026, 1:59 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

NCT00430677
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Corticosteroids (prednisone or prednisolone), Abatacept, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
14
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2015 · Synced Jun 25, 2026, 1:59 PM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

NCT05138133
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Anifrolumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
16
States / cities
Glendale, Arizona • La Palma, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Jun 25, 2026, 1:59 PM EDT
Recruiting No phase listed Observational

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

NCT07175285
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Current standard of care treatment options
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
25
States / cities
Mesa, Arizona • La Jolla, California • La Palma, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jun 25, 2026, 1:59 PM EDT
Completed Not applicable Interventional Results available

Individualized Patient Decision Making for Treatment Choices Among Minorities With Lupus

NCT02319525
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Computerized patient decision-aid, Usual care (lupus pamphlet)
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Jun 25, 2026, 1:59 PM EDT
Completed Phase 1 Interventional

Cyclophosphamide and Fludarabine to Treat Lupus Nephritis

NCT00001676
View directory record Official record
Conditions
Glomerulonephritis, Lupus Nephritis, Systemic Lupus Erythematosus
Interventions
SQ Fludarabine
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 25, 2026, 1:59 PM EDT
Recruiting Phase 1 Interventional

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

NCT07115745
View directory record Official record
Conditions
Refractory Autoimmune Diseases
Interventions
BMS-986515, Fludarabine, Cyclophosphamide, Tocilizumab
Genetic · Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 25, 2026, 1:59 PM EDT